Now showing items 1-3 of 3
Trends in oral anticoagulant use in Qatar: a 5-year experience
(
Springer New York LLC
, 2017 , Article)
In Qatar, dabigatran was introduced in 2011 followed by rivaroxaban in 2014. In this study, we aim to explore the trends in oral anticoagulant use in Qatar over the past 5 years and to what extent did DOACs replace warfarin. ...
Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review
(
Springer Nature
, 2022 , Article)
Venous thromboembolism (VTE) is a leading cause of morbidity and mortality globally. The direct oral anticoagulants, including rivaroxaban, are relatively novel therapeutic options in the treatment and prevention of VTE. ...
Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data
(
Springer Science and Business Media Deutschland GmbH
, 2023 , Article)
Purpose
To investigate real-world prescribing trends and clinical outcomes based on body mass index (BMI) categorization in patients who received rivaroxaban therapy.
Methods
This was a retrospective cohort study ...